Co-culture of placental stem cells and stem cells from a second source
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-063/00
A61K-035/50
출원번호
UP-0648802
(2006-12-28)
등록번호
US-7700090
(2010-05-20)
발명자
/ 주소
Heidaran, Mohammad
Wang, Jia-Lun
Ye, Qian
Zeitlin, Andrew
Dulaney, Colleen Suzanne
출원인 / 주소
Anthrogenesis Corporation
대리인 / 주소
Jones Day
인용정보
피인용 횟수 :
45인용 특허 :
141
초록▼
The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a comb
The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
대표청구항▼
What is claimed is: 1. A combined cell population comprising a number of cells in vitro, said number of cells comprising isolated nucleated placental cells that comprise placental stem cells, and comprising stem cells from a second source, wherein said combined cell population, when cultured for a
What is claimed is: 1. A combined cell population comprising a number of cells in vitro, said number of cells comprising isolated nucleated placental cells that comprise placental stem cells, and comprising stem cells from a second source, wherein said combined cell population, when cultured for a time and under conditions that allow the formation of colony-forming units, produces more colony-forming units than a number of said isolated nucleated placental cells equivalent to the number of cells in the combined cell population or a number of said stem cells from a second source equivalent to the number of cells in the combined cell population, alone, and wherein said isolated nucleated placental cells are obtained by perfusion of a post-partum human placenta by passing a perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta and isolation of said isolated nucleated placental cells from the perfusate, wherein said placenta has been drained of cord blood and flushed to remove residual blood; and wherein said nucleated placental cells are not obtained from cord blood. 2. The combined cell population of claim 1, wherein said isolated nucleated placental cells and stem cells from a second source show improved engraftment when introduced into a recipient compared to a number of isolated nucleated placental cells equivalent to the number of cells in the combined cell population, or a number of stem cells from a second source equivalent to the number of cells in the combined cell population, alone. 3. The combined cell population of claim 1 comprising said isolated nucleated placental cells and said stem cells from a second source in a ratio, out of a plurality of ratios, that, when cultured under conditions allowing the formation of colony forming units, produces the most colony forming units. 4. The combined cell population of claim 1, wherein said stem cells from a second source are cord blood stem cells, bone marrow stem cells, hematopoietic stem cells, or mesenchymal stem cells. 5. The combined cell population of claim 4, wherein said hematopoietic stem cells are cord blood hematopoietic stem cells. 6. The combined cell population of claim 4, wherein said hematopoietic stem cells are CD34+ cells. 7. The combined cell population of claim 1, wherein said placental stem cells comprise CD34+ cells. 8. The combined cell population of claim 1, wherein said placental stem cells comprise CD34+ cells. 9. The combined cell population of claim 1, wherein said placental stem cells comprise cells that are OCT4+ or ABC-p+. 10. The combined cell population of claim 1, wherein said placental stem cells comprise cells that are CD34+ and cells that are OCT4+ or ABC-p+. 11. The combined cell population of claim 1, wherein said placental stem cells are contained within placental perfusate substantially lacking red blood cells and cellular debris. 12. The combined cell population of claim 1, wherein said population comprises placental stem cells isolated from enzyme-digested placental tissue. 13. The combined cell population of claim 1, wherein said isolated nucleated placental cells and said stem cells from a second source are obtained from the same individual. 14. The combined cell population of claim 1, wherein said isolated nucleated placental cells and said stem cells from a second source are obtained from different individuals. 15. The combined cell population of claim 1, wherein said isolated nucleated placental cells are obtained from a plurality of placentas. 16. The combined cell population of claim 1, wherein said stem cells from a second source are obtained from a plurality of individuals. 17. A method of transplantation, comprising transplanting to a recipient a combined cell population comprising a number of isolated nucleated placental cells that comprise placental stem cells, and comprising stem cells from a second source, wherein said combined stem cell population, when transplanted, results in enhanced engraftment compared to transplantation of a number of isolated nucleated placental cells equivalent to the number of cells in the combined stem cell population, or stem cells from a second source equivalent to the number of cells in the combined stem cell population, alone, and wherein said isolated nucleated placental cells are obtained by perfusion of a post-partum human placenta by passing a perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta and isolation of said isolated nucleated placental cells from the perfusate; wherein said placenta has been drained of cord blood and flushed to remove residual blood; and wherein said nucleated placental cells are not obtained from cord blood. 18. The method of claim 17, wherein the combined cell population comprises said isolated placental cells and stem cells from a second source in a ratio that, when said combined cell population is cultured for a time and under conditions sufficient to allow formation of colony-forming units, produces a greater number of colony-forming units than a number of said nucleated placental cells equivalent to the number of cells in the combined cell population, or a number of said stem cells from a second source equivalent to the number of cells in the combined cell population, alone. 19. The method of claim 18, wherein said ratio is selected by selecting, within a plurality of ratios of said isolated nucleated placental cells and stem cells from a second source cultured for a time and under conditions sufficient to allow the formation of colony-forming units, a ratio that produces the greatest number of colony-forming units. 20. The method of claim 17, wherein said stem cells from a second source are cord blood stem cells, bone marrow stem cells, hematopoietic stem cells, or mesenchymal stem cells. 21. The method of claim 17, wherein said stem cells from a second source are hematopoietic stem cells. 22. The method of claim 21, wherein said hematopoietic stem cells are cord blood hematopoietic stem cells. 23. The method of claim 21, wherein said hematopoietic stem cells are CD34+ cells. 24. The method of claim 18, wherein the placental perfusate cells comprise CD34+ cells. 25. The method of claim 18, wherein the placental perfusate cells comprise cells that are CD34+ and cells that are OCT4+ or ABC-p+. 26. The method of claim 18, wherein said isolated nucleated placental cells are contained within placental perfusate substantially lacking red blood cells and cellular debris. 27. The method of claim 18, wherein said composition comprises placental stem cells isolated from enzyme-digested placental tissue. 28. The method of claim 18, wherein said transplantation results in a statistically significantly enhanced engraftment of CD34+ or CD45+ cells in said recipient as compared to transplantation of a number of stem cells from a second source equivalent to the number of cells in the combined cell population alone. 29. The method of claim 18, wherein said transplantation results in a statistically significantly higher engraftment of CD34+ or CD45+ cells in said recipient as compared to transplantation of a number of cord blood stem cells equivalent to the number of cells in the combined cell population alone. 30. The method of claim 18, wherein the ratio of said isolated nucleated placental cells and said hematopoietic stem cells is from about 1:100 to about 100:1 at the time of transplantation, as determined by total numbers of nucleated cells. 31. The method of claim 30, wherein the ratio of said isolated nucleated placental cells and said hematopoietic stem cells is from about 1:10 to about 10:1 at the time of transplantation, as determined by the total numbers of nucleated cells. 32. A composition comprising a combined cell population in a container, wherein said combined stem cell population comprises a number of isolated nucleated placental cells comprising placental stem cells, and stem cells from a second source, wherein said composition produces detectably higher engraftment in an individual receiving the composition, compared to an individual who receives said number of isolated nucleated placental cells or said number of stem cells from a second source, alone, and wherein said isolated nucleated placental cells are obtained by perfusion of a post-partum human placenta by passing a perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta and isolation of said isolated nucleated placental cells from the perfusate; wherein said placenta has been drained of cord blood and flushed to remove residual blood; and wherein said nucleated placental cells are not obtained from cord blood. 33. The composition of claim 32, wherein the container is a bag, flask, or jar. 34. The composition of claim 32, wherein said isolated nucleated placental cells and said stem cells from a second source are contained together in a bag. 35. The composition of claim 32, wherein said isolated nucleated placental cells and said stem cells from a second source are contained separately within a bag. 36. The composition of claim 32, wherein said composition comprises one or more compounds that facilitate cryopreservation of the combined cell population. 37. The composition of claim 32, wherein said combined cell population is contained within a physiologically-acceptable aqueous solution. 38. The composition of claim 37, wherein said physiologically-acceptable aqueous solution is a 0.9% NaCl solution. 39. The composition of claim 33, wherein said bag is a sterile plastic bag. 40. The composition of claim 39, wherein said bag allows or facilitates intravenous administration of said combined cell population. 41. The composition of claim 32, wherein said combined cell population comprises isolated nucleated placental cells that are HLA-matched to said stem cells from a second source. 42. The composition of claim 32, wherein said combined cell population comprises isolated nucleated placental cells that are at least partially HLA-mismatched to said stem cells from a second source. 43. The composition of claim 32, wherein said isolated nucleated placental perfusate cells are derived from a plurality of donors. 44. The composition of claim 32, wherein said stem cells from a second source are derived from a plurality of donors. 45. The composition of claim 32, where said placental stem cells, said stem cells from a second source, or both have been passaged at least two times. 46. The composition of claim 32, where said placental stem cells, said stem cells from a second source, or both have been passaged at least five times. 47. The composition of claim 32, where said placental stem cells, said stem cells from a second source, or both have been passaged at least 10 times. 48. The composition of claim 32, where said placental stem cells, said stem cells from a second source, or both have been passaged at least 15 times. 49. The composition of claim 32, where said placental stem cells, said stem cells from a second source, or both have been passaged at least 20 times.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (141)
Pittenger Mark F., Adipogenic differentiation of human mesenchymal stem cells.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Compositions containing cultured mitotic human stem cells.
Caplan Arnold I. ; Haynesworth Stephen E. ; Gerson Stanton L. ; Lazarus Hillard M., Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells.
Bauer S. Christopher ; Abrams Mark Allen ; Braford-Goldberg Sarah Ruth ; Caparon Maire Helena ; Easton Alan Michael ; Klein Barbara Kure ; McKearn John Patrick ; Olins Peter O. ; Paik Kumnan ; Thomas, Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines.
Bjornson Christopher R. ; Rietze Rod L.,AUX ; Reynolds Brent A.,CAX ; Vescovi Angelo L.,ITX, Generation of hematopoietic cells from multipotent neural stem cells.
Nakahata Tatsutoshi (Matsumoto JPX) Kawano Genji (Kamakura JPX) Sudo Tetsuo (Kamakura JPX) Kojima Katsuaki (Yokohama JPX), Hematopoietic stem cell growth-promoting compositions containing a fibroblast-derived fragment of fibronectin and a grow.
Rubinstein Pablo ; Coelho Philip Henry ; Stevens Cladd E., High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjuncti.
Janice M. Davis-Sproul ; Mark Aaron Moorman ; Renee Marie McNeil ; Donald William Simonetti, Jr. ; Lora Catherine Hammill ; Stewart Craig, Human mesenchymal stem cells.
Srour Edward (Indianapolis IN) Zanjani Esmail (Reno NV) Brandt John E. (Indianapolis IN) Hoffman Ronald (Indianapolis IN), Human stem cell compositions and methods.
Tsukamoto Ann (Palo Alto CA) Baum Charles M. (Mountain View CA) Aihara Yukoh (Yokohama JPX) Weissman Irving (Palo Alto CA), Identification and isolation of human hematopoietic stem cells.
Prockop Darwin J. ; Pereira Ruth F. ; Leeper Dennis B. ; O'Hara Michael D., Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects.
Edward A. Boyse ; Hal E. Broxmeyer ; Gordon W. Douglas, Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
Boyse Edward A. (Tucson AZ) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of the.
Kevin R. McIntosh ; Joseph D. Mosca ; Elena N. Klyushnenkova, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh Kevin R. ; Mosca Joseph D. ; Klyushnenkova Elena N., Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh, Kevin R.; Mosca, Joseph D.; Klyushnenkova, Elena, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultur.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for treating connective tissue disorders.
Murray Lesley (San Jose CA) Sutherland D. Robert (Oakville CAX), Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby an.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI) Schwartz Richard M. (Ann Arbor MI), Methods and compositions for the ex vivo replication of human hematopoietic stem cells.
Emerson Stephen G. ; Clarke Michael F. ; Palsson Bernhard O., Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 sec.
Fei Rui G. (Seattle WA) Heimfeld Shelly (Woodinville WA) Minshall Billy W. (Mill Creek WA) Berenson Ronald J. (Mercer Island WA), Methods and device for culturing human hematopoietic cells and their precursors.
Anderson David J. ; Shah Nirao M., Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-.beta. super family growth factors.
Csete Marie ; Doyle John ; Wold Barbara, Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells.
Palsson Bernhard O. (Ann Arbor MI) Armstrong R. Douglas (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Emerson Stephen G. (Ann Arbor MI), Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods for the ex vivo replication of human stem cells and/or expansion of human progenitor cells.
Hill Beth Louise ; Rozler Elen ; Chen Benjamin P., Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods, compositions and devices for growing human hematopoietic cells.
Palsson Bernhard O. ; Emerson Stephen G. ; Schwartz Richard M., Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells.
Hariri,Robert J.; Stirling,David I.; Moutouh De Parseval,Laure A.; Chan,Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
Boyse Edward A. (New York NY) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
McIntosh, Kevin; Klyushnenkova, Elena, Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation.
Gerson Stanton L. (Pepper Pike OH) Caplan Arnold I. (Cleveland Heights OH) Haynesworth Stephen E. (Cleveland Heights OH), Transduced mesenchymal stem cells.
Hessel Stephen R. (Fountain Valley CA) Young H. Theodore (Lake Forest CA) Katz Michael (Richmond CA), Umbilical cord clamping, cutting, and blood collecting device and method.
Zeitlin, Andy; Russotti, Gregory; He, Shuyang; Pal, Ajai; Chen, Hong J.; Brieva, Thomas; Shorr, Ryan; Murphy, Brian, Cell composition and methods of making the same.
Heidaran, Mohammad; Wang, Jia-Lun; Ye, Qian; Zeitlin, Andrew; Delaney, Colleen Suzanne, Co-culture of placental stem cells and stem cells from a second source.
Abramson, Sascha D.; Guelakis, Marian; Heidaran, Mohammad A.; Labazzo, Kristen; Yaccoby, Shmuel, Methods and compositions for treatment of bone defects with placental cell populations.
Edinger, James W.; Hariri, Robert J.; Wang, Jia-Lun; Ye, Qian; Labazzo, Kristen S.; Pereira, Marian; Abramson, Sascha Dawn, Methods and compositions for treatment of bone defects with placental cell populations.
Edinger, James W.; Hariri, Robert J.; Wang, Jia-Lun; Ye, Qian; Labazzo, Kristen S.; Pereira, Marian; Abramson, Sascha Dawn, Methods and compositions for treatment of bone defects with placental cell populations.
Edinger, James W.; Hariri, Robert J.; Wang, Jia-Lun; Ye, Qian; Labazzo, Kristen S.; Pereira, Marian; Abramson, Sascha Dawn, Methods and compositions for treatment of bone defects with placental cell populations.
Hariri, Robert J.; Stirling, David I.; Moutouh-De Parseval, Laure A.; Chan, Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
Paludan, Casper; Edinger, James W.; Harbacheuski, Ryhor; Murray, RoseAnn; Hariri, Robert J., Treatment of multiple sclerosis using placental stem cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.